AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

AbbVie (ABBV) stock in focus after a Phase 3 trial setback for leukemia therapy venetoclax marketed with Roche (RHHBY) in ...